ProLynx Inc is a clinical-stage biopharmaceutical company specializing in the development of novel long-acting therapeutics. We are leveraging our drug delivery platform technology to enhance the delivery, half-life, efficacy, and safety of drugs. ProLynx’s technology enables predictable and controllable half-life extension of drugs – including peptides, proteins and small molecules – using nano, macromolecular and fix supports (SC, IV & IT injectables, implants, and others). This technology improves the pharmacokinetics, pharmacodynamics, and reduced dosing frequency compared to conventional delivery methods.